MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet

NCT02805738 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2016-06-21

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet

Conditions

Interventions

DRUG

CKD-390

CKD-390 1 Tablet (48 weeks)

DRUG

viread

viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Kwan Sik lee, MD · Kangnam severance hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-11-30
Completion
2018-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02805738 on ClinicalTrials.gov